$2.73
5.00% yesterday
Nasdaq, Dec 24, 08:27 pm CET
ISIN
US2075231017
Symbol
CNTB

Connect Biopharma Holdings Ltd - ADR Stock price

$2.73
-0.18 6.19% 1M
+1.77 185.65% 6M
+1.35 97.83% YTD
+1.73 174.10% 1Y
+1.97 261.54% 3Y
-14.27 83.94% 5Y
-14.27 83.94% 10Y
-14.27 83.94% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.13 5.00%
ISIN
US2075231017
Symbol
CNTB
Industry

Key metrics

Basic
Market capitalization
$152.6m
Enterprise Value
$97.8m
Net debt
positive
Cash
$54.8m
Shares outstanding
55.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.8 | 510.1
EV/Sales
3.8 | 327.0
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-95.8%
ROIC
-517.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$26.1m | $299.2k
EBITDA
$-52.8m | -
EBIT
$-53.6m | $-283.3m
Net Income
$-45.7m | $-274.5m
Free Cash Flow
$-56.3m
Growth (TTM | estimate)
Revenue
- | -98.9%
EBITDA
- | -
EBIT
- | -1,285.1%
Net Income
- | -1,656.3%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
-202.5% | -
EBIT
-205.2%
Net
-175.2% | -91,745.0%
Free Cash Flow
-215.8%
More
EPS
$-0.8
FCF per Share
$-1.0
Short interest
0.3%
Employees
62
Rev per Employee
$420.0k
Show more

Is Connect Biopharma Holdings Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

Buy
90%
Hold
10%

Financial data from Connect Biopharma Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
26 26
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
-
112%
- Research and Development Expense 48 48
-
185%
-53 -53
-
-202%
- Depreciation and Amortization 0.71 0.71
-
3%
EBIT (Operating Income) EBIT -54 -54
-
-205%
Net Profit -46 -46
-
-175%

In millions USD.

Don't miss a Thing! We will send you all news about Connect Biopharma Holdings Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesda...
Neutral
GlobeNewsWire
about one month ago
– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for the treatment of atopic dermatitis submitted by Simcere, the Company's exclusive licensee in Greater China, was accepted by China's NMPA – – Completed termination of American Depositary Receipt ...
Neutral
Seeking Alpha
about 2 months ago
Connect Biopharma Holdings Limited ( CNTB ) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST Company Participants Barry Quart - CEO & Director Conference Call Participants Craig Brelsford Presentation Craig Brelsford Hello. This is Craig Brelsford with RedChip Companies.
More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office Cayman Islands
CEO Barry Quart
Employees 62
Founded 2015
Website www.connectbiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today